Tyler Van Buren
Stock Analyst at TD Cowen
(3.21)
# 2,553
Out of 5,182 analysts
65
Total ratings
48.08%
Success rate
3.2%
Average return
Main Sectors:
Stocks Rated by Tyler Van Buren
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $880 → $960 | $751.57 | +27.73% | 8 | Apr 23, 2026 | |
| SLNO Soleno Therapeutics | Downgrades: Hold | $85 → $53 | $52.72 | +0.53% | 2 | Apr 7, 2026 | |
| BHVN Biohaven | Maintains: Buy | $15 → $30 | $9.88 | +203.64% | 4 | Mar 11, 2026 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $30 → $35 | $23.26 | +50.47% | 1 | Feb 26, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintains: Hold | $40 → $45 | $48.79 | -7.76% | 3 | Feb 13, 2026 | |
| CCCC C4 Therapeutics | Initiates: Buy | n/a | $2.88 | - | 1 | Dec 2, 2025 | |
| MBX MBX Biosciences | Initiates: Buy | n/a | $31.96 | - | 1 | Nov 4, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $30 → $40 | $40.50 | -1.23% | 2 | Oct 31, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $60 → $95 | $73.28 | +29.64% | 2 | Oct 30, 2025 | |
| GILD Gilead Sciences | Maintains: Buy | $115 → $125 | $130.40 | -4.14% | 6 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $30.73 | - | 1 | Jul 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $68.68 | - | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $11.51 | - | 2 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $22.65 | - | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $69.03 | - | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $70 → $60 | $50.73 | +18.27% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $10.32 | - | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $6.75 | - | 1 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $28.54 | - | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $29.72 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $69.67 | - | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $115.03 | - | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $85.61 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.33 | - | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $29.30 | +138.91% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.98 | - | 1 | Jul 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.44 | - | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $37.59 | - | 1 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $225 | $24.82 | +806.53% | 1 | Feb 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $875 | $6.40 | +13,571.88% | 1 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $16.68 | +139.81% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $30 | $16.46 | +82.26% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.24 | +3,932.26% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $0.36 | +8,171.30% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $13.53 | - | 1 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $30.64 | - | 1 | Aug 4, 2017 |
Regeneron Pharmaceuticals
Apr 23, 2026
Maintains: Buy
Price Target: $880 → $960
Current: $751.57
Upside: +27.73%
Soleno Therapeutics
Apr 7, 2026
Downgrades: Hold
Price Target: $85 → $53
Current: $52.72
Upside: +0.53%
Biohaven
Mar 11, 2026
Maintains: Buy
Price Target: $15 → $30
Current: $9.88
Upside: +203.64%
Arcutis Biotherapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $30 → $35
Current: $23.26
Upside: +50.47%
CRISPR Therapeutics AG
Feb 13, 2026
Maintains: Hold
Price Target: $40 → $45
Current: $48.79
Upside: -7.76%
C4 Therapeutics
Dec 2, 2025
Initiates: Buy
Price Target: n/a
Current: $2.88
Upside: -
MBX Biosciences
Nov 4, 2025
Initiates: Buy
Price Target: n/a
Current: $31.96
Upside: -
Travere Therapeutics
Oct 31, 2025
Maintains: Buy
Price Target: $30 → $40
Current: $40.50
Upside: -1.23%
BridgeBio Pharma
Oct 30, 2025
Maintains: Buy
Price Target: $60 → $95
Current: $73.28
Upside: +29.64%
Gilead Sciences
Oct 23, 2025
Maintains: Buy
Price Target: $115 → $125
Current: $130.40
Upside: -4.14%
Jul 22, 2025
Initiates: Buy
Price Target: n/a
Current: $30.73
Upside: -
Jan 7, 2025
Initiates: Buy
Price Target: n/a
Current: $68.68
Upside: -
Dec 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $11.51
Upside: -
Oct 8, 2024
Initiates: Buy
Price Target: n/a
Current: $22.65
Upside: -
Sep 16, 2024
Initiates: Buy
Price Target: n/a
Current: $69.03
Upside: -
Sep 13, 2024
Maintains: Hold
Price Target: $70 → $60
Current: $50.73
Upside: +18.27%
Aug 13, 2024
Initiates: Buy
Price Target: n/a
Current: $10.32
Upside: -
Aug 6, 2024
Initiates: Buy
Price Target: n/a
Current: $6.75
Upside: -
Jun 24, 2024
Initiates: Buy
Price Target: n/a
Current: $28.54
Upside: -
May 15, 2024
Initiates: Buy
Price Target: n/a
Current: $29.72
Upside: -
Nov 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $69.67
Upside: -
Oct 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $115.03
Upside: -
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $85.61
Upside: -
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.33
Upside: -
Aug 8, 2022
Initiates: Outperform
Price Target: $70
Current: $29.30
Upside: +138.91%
Jul 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $3.98
Upside: -
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.44
Upside: -
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $37.59
Upside: -
Feb 10, 2021
Initiates: Overweight
Price Target: $225
Current: $24.82
Upside: +806.53%
Nov 10, 2020
Initiates: Overweight
Price Target: $875
Current: $6.40
Upside: +13,571.88%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $16.68
Upside: +139.81%
Aug 10, 2020
Maintains: Overweight
Price Target: $35 → $30
Current: $16.46
Upside: +82.26%
Jun 29, 2020
Initiates: Overweight
Price Target: $50
Current: $1.24
Upside: +3,932.26%
Apr 22, 2020
Initiates: Overweight
Price Target: $30
Current: $0.36
Upside: +8,171.30%
Nov 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $13.53
Upside: -
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $30.64
Upside: -